Use of cyclophilin D or creatine kinase for inhibiting apoptosis, useful for treating e.g. cardiac infarct and in drug screening, also use of their inhibitors for treating tumors

摘要

Use of cyclophilin D (I) and/or creatine kinase (II), or their biologically active fragments or derivatives; nucleic acids that encode them, and their activators (collectively (A)), for inhibiting apoptotic processes that are not associated with ANT-1 (adenine nucleotide translocase-1). Independent claims are also included for the following: (1) pharmaceutical composition containing (i) fusion protein of (I) or (II) with a heterologous protein, (ii) a derivative of (I) without chaperone function, (iii) a derivative of (II) without enzymatic activity and (iv) nucleic acid encoding (i)-(iii); (2) use of an inhibitor of (I) or (II) for inhibiting hyperproliferation and/or autoimmune processes; (3) transgenic non-human organism, or eukaryotic cell, that under- or over-expresses (I) and/or (II); and (4) use of an effector molecule directed against the amino acid regions 1-17, 67-107 and/or 151-170 regions of ANT-1 for modulating ANT-1 associated apoptosis. ACTIVITY : Cardiant; Cerebroprotective; Vasotropic; Nootropic; Neuroprotective; Antiparkinsonian; Ophthalmological; Hepatotropic; Antianemic; Anti-AIDS; Cytostatic; Immunosuppressive; Nephrotropic; Virucide. No details of tests for these activities are given. MECHANISM OF ACTION : (A) inhibit apoptotic processes associated with: activation of permeability transition pores; caspase 8, tBid and/or bax; inhibitors of tumor necrosis factor/cycloheximide; UV light and/or diarsenic trioxide; cytostatics or hypoxia. No biological data given.